Name | Number of supported studies | Average coverage | |
---|---|---|---|
Mueller cell | 3 studies | 21% ± 4% |
Insufficient scRNA-seq data for expression of CNMD at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 97% | 144.45 | 2553 / 2642 | 50% | 3.35 | 354 / 705 |
thymus | 78% | 59.75 | 512 / 653 | 45% | 13.86 | 271 / 605 |
prostate | 29% | 10.60 | 71 / 245 | 31% | 1.26 | 155 / 502 |
pancreas | 14% | 3.00 | 45 / 328 | 23% | 0.73 | 41 / 178 |
spleen | 23% | 4.49 | 56 / 241 | 0% | 0 | 0 / 0 |
lung | 6% | 3.27 | 32 / 578 | 16% | 19.26 | 190 / 1155 |
esophagus | 11% | 3.68 | 152 / 1445 | 5% | 0.16 | 10 / 183 |
ovary | 2% | 0.70 | 3 / 180 | 9% | 0.75 | 37 / 430 |
adrenal gland | 1% | 0.33 | 2 / 258 | 7% | 0.55 | 17 / 230 |
stomach | 1% | 0.10 | 2 / 359 | 7% | 0.34 | 21 / 286 |
uterus | 1% | 0.10 | 1 / 170 | 7% | 0.99 | 32 / 459 |
eye | 0% | 0 | 0 / 0 | 8% | 0.27 | 6 / 80 |
intestine | 4% | 1.00 | 34 / 966 | 3% | 0.08 | 15 / 527 |
breast | 2% | 0.58 | 11 / 459 | 2% | 1.88 | 26 / 1118 |
kidney | 0% | 0 | 0 / 89 | 4% | 3.45 | 40 / 901 |
bladder | 0% | 0 | 0 / 21 | 4% | 2.14 | 19 / 504 |
skin | 1% | 0.30 | 11 / 1809 | 3% | 0.11 | 13 / 472 |
tonsil | 0% | 0 | 0 / 0 | 2% | 1.05 | 1 / 45 |
peripheral blood | 2% | 0.56 | 18 / 929 | 0% | 0 | 0 / 0 |
heart | 1% | 0.11 | 5 / 861 | 0% | 0 | 0 / 0 |
liver | 0% | 0 | 0 / 226 | 0% | 0.05 | 2 / 406 |
adipose | 0% | 0.09 | 4 / 1204 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
blood vessel | 0% | 0 | 0 / 1335 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0001501 | Biological process | skeletal system development |
GO_0001937 | Biological process | negative regulation of endothelial cell proliferation |
GO_0006029 | Biological process | proteoglycan metabolic process |
GO_0030154 | Biological process | cell differentiation |
GO_0051216 | Biological process | cartilage development |
GO_0016525 | Biological process | negative regulation of angiogenesis |
GO_0012505 | Cellular component | endomembrane system |
GO_0005576 | Cellular component | extracellular region |
GO_0016020 | Cellular component | membrane |
Gene name | CNMD |
Protein name | Leukocyte cell-derived chemotaxin 1 (Chondromodulin) Leukocyte cell-derived chemotaxin 1 (Chondromodulin) [Cleaved into: Chondrosurfactant protein (CH-SP); Chondromodulin-1 (Chondromodulin-I) (ChM-I)] |
Synonyms | LECT1 MYETS1 CHMI |
Description | FUNCTION: Bifunctional growth regulator that stimulates the growth of cultured chondrocytes in the presence of basic fibroblast growth factor (FGF) but inhibits the growth of cultured vascular endothelial cells. May contribute to the rapid growth of cartilage and vascular invasion prior to the replacement of cartilage by bone during endochondral bone development. Inhibits in vitro tube formation and mobilization of endothelial cells. Plays a role as antiangiogenic factor in cardiac valves to suppress neovascularization. . |
Accessions | E9PKI9 ENST00000377962.8 [O75829-1] ENST00000448904.6 [O75829-2] ENST00000431550.1 O75829 |